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Summary
Objective: To investigate whether fibronectin fragments (Fn-fs), shown to damage cultured cartilage, can be found in
cartilage from patients with osteoarthritis (OA) or rheumatoid arthritis, or can be generated from fibronectin (Fn)
within synovial fluids or from Fn in the matrix of cultured cartilage. To also determine whether cartilage or synovial
fluid Fn-fs are active and, thus, could contribute to cartilage damage in vivo.
Methods: Fn-fs were immunochemically identified in cartilage extracts from patients with OA or rheumatoid arthritis
or in bovine cartilage cultured with IL-1a or in bovine synovial fluids treated with stromelysin-1 (MMP-3). The effect
of removal of Fn-fs from OA synovial fluids was tested by passing fluids over an anti-Fn column and adding the resultant
fluids to bovine cartilage cultures to measure proteoglycan (PG) degradation. Gelatin–Sepharose purified Fns from
bovine plasma, synovial fluid or cartilage were digested with MMP-3 and the Fn-fs tested for degradation of PG in
cultured cartilage.
Results: Extracts of cartilage from patients with rheumatoid arthritis or with OA contained a range of Fn-fs. Removal
of Fn-fs from OA synovial fluids significantly reduced the resultant damage when the fluids were added to cultured
cartilage. Addition of IL-1a to cultured cartilage or of MMP-3 to synovial fluids enhanced generation of Fn-fs. Fn-fs,
whether derived from bovine plasma or synovial fluid or cartilage Fns, damaged cartilage.
Conclusions: These data demonstrate that although Fn-fs could be generated in vivo within synovial fluids and Fn-fs
found in OA synovial fluid may contribute to cartilage damage in vivo, Fn-fs could also be generated within cartilage
and amplify cartilage damage. Thus, Fn-fs may be both autocrine and paracrine regulators of cartilage metabolism.
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Introduction
Fibronectin (Fn) is an extracellular matrix and
circulating protein that is easily degraded into
fragments (Fn-fs) by many different types of
proteinases. Levels of Fn-fs are greatly elevated in
synovial fluids of patients with osteoarthritis (OA)
and rheumatoid arthritis (RA) [1–5]. This has great
relevance since we have shown that Fn-fs
up-regulate matrix metalloproteinase (MMP) ex-
pression in articular cartilage [6] and suppress
synthesis of proteoglycan (PG) [7]. Both activities
result in severe cartilage damage in vitro [6]. We
have also shown that injection of Fn-fs into rabbit
knee joints causes up to 50% removal of total
articular cartilage PG within 7 days [8]. The Fn-fs
appear to exert their action by binding to the
superficial surface of cartilage and penetrating the
tissue [9]. The Fn-fs may operate through the Fn
receptor since antibodies to the alpha5beta1
integrin receptor also suppress PG synthesis, as do
Fn-fs (unpublished) and analog peptides of the
Ar–Gly–Asp–Ser integrin-binding sequence block
activities of the Fn-fs [10]. The Fn-fs cause release
of the catabolic cytokines, TNF-a, IL-1a, IL-1b and
IL-6, which appear to be responsible for the
observed stromelysin-1 (MMP-3) induction and the
suppression of PG synthesis [11, 12]. An interesting
feature of this system is that one of the major
MMPS the Fn-fs induce is MMP-3 [6, 13–15] which
can degrade native Fn into Fn-fs as shown by
others [16, 17] and thus, amplify its own synthesis.
Our objectives here were to investigate several
aspects that might contribute to our understand-
ing of the physiologic relevance of Fn-fs to
cartilage pathology. We investigated whether the
small Fn-fs found by us to be highly active in
cartilage damage could be found in OA and RA
cartilage and whether the Fn-fs found in OA
synovial fluids contribute to the cartilage chon-
drolytic activities of the fluid. We also investigated
whether Fn-fs can be found in IL-1a treated
cartilage tissue or in MMP-3 treated synovial fluid
Received 10 October 1997; accepted 26 January 1998.
Address correspondence to: Dr Gene A. Homandberg. Phone:
(312) 942-5468; Fax: (312) 942-3053
231
Homandberg et al.: Cartilage and synovial fluid fibronectin fragments232
and whether MMP-3 generated Fn-fs from plasma
Fn, synovial fluid Fn or cartilage Fn are equally
active in cartilage damage. Our data support the
notion of an active role for Fn-fs in cartilage
pathology.
Materials and Methods
All common chemicals were from Sigma Chemi-
cal Co. (St. Louis, MO, U.S.A.), unless otherwise
noted. Procion Red-Sepharose (Sigma H-E3B, also
Reactive Red 120), bovine plasma, fractionated
goat anti-sera to human Fn (66 mg protein/ml;
product ( F-1509); IgG fraction of goat anti-sera
to human IgG (whole molecule) (2 mg/ml; product
( I-1886); affinity isolated rabbit anti-goat IgG
(whole molecule) coupled with horse radish
peroxidase (50 peroxidase U/ml; product ( A-3540)
were from Sigma Chem. Co. Protein G-125I was
from ICN Biomedicals, Inc. (Costa Mesa, CA,
U.S.A.). A mouse monoclonal antibody directed
toward the N-terminal region of human plasma Fn,
MAB1936, was from Chemicon International, Inc.
(Temecula, CA, U.S.A.). A monoclonal antibody to
human MMP-3 was from Oncogene Sciences
(Cambridge, MA, U.S.A.). Recombinant human
IL-1a was from Endogen, Inc. (Cambridge, MA,
U.S.A.). Iodo-beads were from Pierce Chemical
Co. (Rockford, IL, U.S.A.). Bovine plasma was
purchased from Pell-Freez Biologicals (Rogers,
AR, U.S.A.).
extraction of protein from oa and ra
cartilage
Knee articular cartilage from patients with RA
or OA or from normal donors was subjected to
extraction with 4 m GuHCl–0.05 m sodium acetate
for 8 h at 4° C and the extract then dialyzed against
water to remove salt. Protein concentrations were
determined by the Bio-Rad protein assay. An
aliquot representing 10 mg protein was applied to
10% acrylamide sodium dodecyl sulfate (SDS) gels
for Western blotting. OA was diagnosed based on
clinical features substantiated by radiological
evidence. RA was diagnosed based on the
American College of Rheumatology criteria [18].
During dissection, care was taken not to remove
underlying subchondral bone.
western blots
Western blotting was performed as described [13]
using a 125-fold dilution of goat anti-sera to human
plasma Fn (final 4 mg/ml protein) in 150 mm NaCl,
50 mm Tris buffer, pH 7.4, for 8 h or a 200-fold
dilution of the MAB1936 antibody in the same
buffer. The blots were then treated with either
[125I]-protein G for the anti-Fn as described [13] or
with 10 mg/ml 125I labeled rabbit anti-mouse IgG for
use with the MAB1936 antibody. For Fig. 2 only,
the blots were visualized by first treating for 2 h
with a 100-fold dilution of goat anti-sera to human
Fn, washing several times with Tris-buffered saline
(TBS) and then treating for 2 h with a 500-fold
dilution of rabbit anti-goat IgG coupled with
horseradish peroxidase. To visualize bands a
substrate solution was added, which was prepared
by dissolving 30 mg of 4-chloro-1-naphthol in cold
absolute methanol and diluting with 100 ml of
50 mm Tris buffer, pH 7.6, also 0.3% in hydrogen
peroxide.
removal of Fn and Fn-fs from oa synovial
fluids
Synovial fluids from three different donors were
obtained and used to study the effect of removal
of the Fn-f. Synovial fluids were supplemented
with 0.5% (w/v) EDTA, 10 U/ml Trasylol, 0.5 mm
phenylmethylsulfonyl fluoride and 1 mg/ml pep-
statin within 30 min of collection. To remove
cellular elements, samples were centrifuged at
7000 g for 10 min. Sodium azide was then added
for a final concentration of 0.1% (v/v). An affinity
resin with coupled antibodies to Fn was prepared.
A 1 ml solution of goat antibodies to human plasma
Fn (Sigma Chem. Co.) containing 5 mg/ml protein
was diluted to 10 ml with 0.1 n sodium bicarbonate,
pH 9.5, and mixed with 10 ml of CNBr-activated
Sepharose prepared as described [19]. After 24 h of
reaction, the resin was washed with 1 l of 0.1 m
sodium phosphate, pH 7, and 3 ml resin packed
into a column. Synovial fluids in a 5 ml volume
were passed over the columns and the pass-through
volume recovered. Care was taken not to dilute
the synovial fluid more than about 20%. The
resultant synovial fluids were then diluted with
2 volumes of Dulbecco’s modified Eagle’s
medium (DMEM) and sterile-filtered for testing
cartilage chondrolytic activities. Confirmation
of removal of Fn and Fn-f was performed
semi-quantitatively by subjecting fluids to Western
blotting with goat anti-sera to human Fn before
and after affinity chromatography. As a control,
a 1 ml solution of goat antisera to human IgG
containing 2 mg/ml protein was coupled to
Sepharose as described above and synovial
fluids subjected to chromatography on this
resin. Bound material was recovered by treatment
of resins with 4 m urea–0.1 m sodium acetate,
pH 3.7.
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explant cultures of bovine articular
cartilage
Bovine articular cartilage slices were removed
from the metacarpophalangeal joints of adult
bovine animals (18–20 months old) obtained from
the slaughter house and prepared as described [6].
Culturing of slices of bovine articular cartilage
was performed as described [8], in DMEM
containing 50 U/ml penicillin–streptomycin, with
or without 10% serum, and with 50–80 mg cartilage
per 2 ml. Each culture experiment was performed
with at least three culture wells per datum and
each experiment was performed at least three
times with cartilage collected on a different day.
Data shown are means and s.d. (standard
deviation) values for a single typical cartilage
preparation.
PG content of cartilage
PG was quantified in papain digests of cartilage
as described [6, 7, 9, 10] and data reported as
micrograms of PG per milligram of wet weight
cartilage. Each PG assay was reported as a mean
and s.d. of at least three similar test samples. The
unpaired two-tailed Student’s t-test was used to
determine significance.
treatment of cartilage in culture with IL-1a
Bovine articular cartilage slices were cultured
in DMEM with or without 10% serum and with or
without 50 U/ml IL-1a. At various times, the
conditioned media were recovered, dialyzed
against 10 mm EDTA and concentrated 10-fold for
Western blotting with goat anti-sera to human Fn
as described above. Media were changed every
other day, so each conditioned media sample
corresponded to a 2 day accumulation. The
cartilage from each culture well (about 60 mg) was
extracted with 1 ml of 4 m GuHCl, 10 mm EDTA,
50 mm dithiothreitol, 50 mm sodium acetate buffer,
pH 5, for 8 h at 4 ° C. The extract was dialyzed
against water containing 10 mm EDTA, adjusted to
pH 7.0, and concentrated · 10 on a rotary
evaporator. The samples were then reduced,
subjected to SDS electrophoresis on 10% acryl-
amide gels and the gels Western blotted with goat
anti-sera to human Fn as described above.
radio-labeling of an amino-terminal 29-kDa
Fn-f and treatment of cartilage with the
labeled Fn-f
A 29-kDa amino-terminal Fn-f was radio-labeled
using the Pierce Iodo-bead method. This Fn-f is
liberated by treatment of human plasma Fn
with thrombin and is highly active in cartilage
chondrolysis [6]. To 200 ml of 0.1 m phosphate
buffer, pH 7, were added six beads and 200 mCi
of 125I. After 15 min, a 1 ml solution of 0.5 mg/ml
29-kDa Fn-f in 0.1 m phosphate buffer, pH 7,
was added. After another 15 min, the solution was
removed and subjected to chromatography on
PD-10 de-salting columns to stop the reaction.
The recovered void volume solution was then
dialyzed exhaustively until counts in the
dialyzate were minimal. The specific activity of
the solution was 153 400 dpm/mg protein. The
solution was sterile filtered and each 2 ml
cartilage culture well adjusted to 3 mg/ml of
labeled Fn-f (100 nm). At various times, cultured
cartilage was removed and added to a tube of
3 ml DMEM. After 1 h, the solution was changed
and tissue washed for another hour. It was
found that 2 h of equilibration in media
was required to wash weakly bound label from
the tissue. The tissue was then counted in a
gamma counter and finally weighed in order to
normalize counts per milligram wet weight of
tissue.
preparation of biotinylated Fn-f and
microscopy of cartilage treated with
biotinylated Fn-f
An amino-terminal 29-kDa Fn-f isolated from
human Fn as described [6] was biotinylated
as directed by Pierce Chem. Co. Briefly, 74 ml of
a 1 mg/ml solution of NHS–biotin in water
was added to a 1.0 ml solution of 0.5 mg/ml Fn-f
in 50 mm sodium bicarbonate buffer, pH 8.5.
After 30 min at room temperature, the solution
then dialyzed exhaustively against phosphate
buffer. To each 2-ml culture well, a 50-ml aliquot
of the labeled Fn-f was added. At days 3 and 5
in 10% serum-DMEM culture, fresh labeled
Fn-f and media were added. At 7 days, Fn-f was
removed from the media. Tissue was removed
at various periods, subjected to cryosectioning
and slices reacted first with 100 ml of 3%
hydrogen peroxide for 5 min. Slices were then
reacted with 100 ml of 0.2 mg/ml avidin–
horseradish peroxidase for 1 h. The slices were
then incubated three times for 20 min each
with phosphate buffer. Next, a 100 ml aliquot
of 0.3 mg/ml DAB, 0.006% hydrogen peroxide in
PBS was added. After 2–6 min, the slices were
washed several times with water and the slice
mounted in mounting media from Scientific
Products.
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treatment of synovial fluid with MMP-3
ProMMP-3 was isolated from chondrocyte mono-
layer cultures treated with 100 nm 29-kDa Fn-f in
serum-free DMEM as described [14]. This was a
single band then but was additionally adsorbed to
and eluted from Procion Red–Sepharose as
described [19]. Activation of proMMP-3 was
performed by adjustment of solutions to 10 mm
aminophenylmercuric acetate. Activated MMP-3
solutions were exhaustively dialyzed to remove
APMA prior to use. Synovial fluid was obtained
from bovine metacarpophalangeal joints, adjusted
to 5 mg/ml of activated bovine MMP-3, and allowed
to incubate at 22° C. At various times, aliquots were
withdrawn, denatured, reduced with 100 mm
dithiothreitol and subjected to electrophoresis on
10% acrylamide SDS gels. The gels were then
subjected to Western blotting with goat anti-sera
to human Fn as described above.
isolation of Fns from synovial fluid and
cartilage tissue and generation of Fn-f
To isolate plasma Fn, 10 ml bovine plasma was
passed over a 10 ml column of gelatin–Sepharose
equilibrated in 50 mm sodium phosphate, pH 7,
containing proteinase inhibitors: 10 mm EDTA,
0.1 mm PMSF and 1 U/ml Trasylol. The resin was
then washed with 10 volumes of 1 m NaCl, 50 mm
sodium phosphate, pH 7.4, containing proteinase
inhibitors and finally eluted with the same buffer
adjusted to 4 m urea also containing proteinase
inhibitors. To isolate synovial fluid Fn, 48 ml
synovial fluid from bovine articular joints were
collected, diluted with 4 volumes of 150 mm NaCl,
50 mm phosphate buffer, pH 7.4, containing
proteinase inhibitors and applied to a similar
gelatin–Sepharose column which was washed and
eluted as above. To isolate cartilage Fn, 20 g
bovine articular cartilage were extracted with
0.1 m NaCl, 0.1 m phosphate buffer, pH 7, also
containing 4 m urea and proteinase inhibitors, for
8 h. The extract was then dialyzed against the same
buffer with urea deleted before application to
gelatin–Sepharose. Urea was used rather than
GuHCl in order to minimize the additional
extraction of PGs. The eluted Fn was left in the
elution buffer until use. Protein absorbances were
used to quantify protein yields; an absorbance of
1.24 through a 1 cm light path for a 1 mg/ml
solution was used [20]. The yields of plasma Fn for
three different preparations were 0.22, 0.25 and
0.31 mg/ml plasma. The yields of synovial fluid Fn
from three different preparations were 0.045, 0.06
and 0.09 mg Fn/ml synovial fluid. The yields of
cartilage Fn for three different cartilage isolations
were 0.18, 0.26 and 0.51 mg Fn/mg cartilage. This
compares with yields of about 1 mg/mg wet weight
cartilage for human cartilage [21] and 0.04 mg/mg
for normal canine shoulder joint cartilage [22].
To generate Fn-fs, the Fns were first dialyzed
against 50 mm Tris buffer, pH 7, containing 150 mm
NaCl and 20 mm CaCl2, with three successive
1000-fold volume changes of dialysis buffer in order
to remove proteinase inhibitors. The solutions
were then adjusted to 2 mg/ml activated MMP-3
and incubation allowed to proceed at 22° C. For
tests of cartilage chondrolytic activity, the MMP-3
digests were first treated with an equal volume of
Procein Red–Sepharose to remove the added
MMP-3. The resultant supernatants were also
subjected to casein zymography to visualize
protease activity as described [7] and confirm
removal of MMP-3. Cartilage cultures were then
adjusted to 1 mm concentrations of the MMP-3
digests, based on derivation from a 0.5 mm solution
of Fn. It was assumed that with complete digestion,
each Fn-f would be present at 1 mm. Since the
effects of different Fn-fs are not additive [6] and
each of several major Fn-fs are approximately
equally active in 10% serum cultures [6], we
assumed that different mixtures of Fn-fs which
might vary in exact composition should have
roughly equal activity on a weight basis.
pg-release into media of cartilage cultures
exposed to Fn-f
Rates of release of PG degradation were
measured by assays of amounts of PG released into
the conditioned media as described [6, 7, 10] using
the dimethylmethylene blue (DMB) dye-binding
assay. The PG release was used as an index of
cartilage damage. Each PG assay was reported as
a mean and s.d. of at least three similar test
samples and the data were reported as micrograms
of PG released per milligram of wet weight
cartilage.
Results
a specific amino-terminal 30-kDa cartilage
damaging Fn-f was found in extracts of
cartilage from both ra and oa patients
Extracts of articular knee cartilage from several
donors were subjected to Western blotting using a
specific monoclonal antibody for the N-terminal
region of the Fn-f [23, 24]. This N-terminal region
contains the 29-kDa segment, which we have found
to be highly active in cartilage damage [6]. Fig. 1
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Fig. 1. Western blot of extracts of cartilage from patients with RA and OA Cartilage from three RA, one normal and
three OA patients was extracted as described in Methods and the extracts applied to a 10% acrylamide SDS gel and
the gel blotted onto nitrocellulose. The blot was probed with a monoclonal antibody specific for the amino-terminus
of Fn. Lanes shown are S (molecular weight standards), RA cartilage from three donors (R); normal cartilage (N); and
OA cartilage from three donors (O).
shows that the RA samples contained a range of
Fn-fs from the 230-kDa subunits of native Fn down
to 30-kDa Fn-fs. The degree of fragmentation or the
total amount of Fn forms differed in the three
donors, however all three not only showed
fragmentation but also the presence of 30-kDa
forms. The single normal sample did not show
detectable levels of Fn. The band at the bottom in
the normal sample is from the dye front. One of the
OA samples did not show high levels of Fn forms,
while the other two showed fragmentation of the
same degree as the RA samples. The 30-kDa Fn-f
was not as intense in these samples.
removal of Fn and Fn-fs from human oa
synovial fluid decreased cartilage damaging
activity
In order to investigate the possible contribution
of Fn and Fn-fs to the chondrolytic activity of OA
synovial fluid, Fn and Fn-fs were first removed
from synovial fluids from patients with OA.
Because synovial fluids were not available from
the same donors studied earlier, fluids from three
additional OA patients were studied. The original
and treated synovial fluids were analyzed for Fn
and Fn-f content by Western blot analysis on a 10%
acrylamide gel, followed by reaction of the blot
with anti-Fn as described in Methods. Fig. 2 shows
that the three OA synovial fluids contained Fn-fs
from less than 200-kDa down to 30-kDa as we have
described previously [5] and as also consistent with
the presence of Fn-fs in the OA cartilage extracts
in Fig. 1. The samples were reduced for electro-
phoresis; the major band of less than 250-kDa
(indicated by arrow) corresponds to reduced native
Fn, while the lower bands of lesser intensity
correspond to Fn-fs. Affinity chromatography
removed nearly all of the Fn and Fn-f, as shown in
the column wash (W1, W2, W3) samples while
treatment of the resins with 4 m urea–0.1 m sodium
acetate, pH 3.7, recovered the Fn and Fn-f, as
shown in the bound (B1, B2, B3) samples.
Chromatography of the OA1 synovial fluid sample
over a nonspecific goat anti-human IgG column did
not significantly remove the Fn or Fn-f as shown in
the nonspecific wash lane (NSW1), confirming the
specificity of the affinity step.
The affinity resin treated fluids were then tested
for cartilage damaging activities. The synovial
fluids were substituted for culture media. Two
culture wells were used for each of the three fluid
samples and the results of all six wells were
averaged. Depletion of PG content was used as an
index of cartilage damage. Control bovine carti-
lage incubated in DMEM alone for 5 days, or with
OA synovial fluid/DMEM or with Fn and Fn-f
depleted synovial fluid/DMEM showed PG con-
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Fig. 2. Western blot of OA synovial fluids, anti-Fn treated synovial fluids and recovered Fn-fs OA synovial fluids were
applied to goat anti-Fn Sepharose and the pass-through collected as described in Methods. Bound material was eluted
as also described in Methods. Reduced samples representing 10 ml of the original synovial fluid volume were applied
to a 9% acrylamide SDS gel. An empty lane was left between each sample lane in order to minimize smearing and
lanes from several gels were photographed and assembled into this composite. Lanes are the fluids before
chromatography (OA1, OA2, OA3), the respective column washes (W1, W2, W3) and the respective bound and eluted
protein (B1, B2, B3). NSW1 corresponds to the column wash of OA1 fluid passed over a column of goat anti-human
IgG. Size standards are shown on the left, as well as the position of the reduced Fn subunits (arrow).
tents of 32.3 ( 2 ) 1.4 mg PG/mg cartilage (N = 6),
25.0 ( 2 ) 2.8 (N = 6) and 30.5 ( 2 ) 2.8 (N = 6),
respectively. Statistical analysis showed that the
OA synovial fluids had significant PG depletion
activity compared to control of DMEM alone
(P = 0.0002) and that depletion of Fn and Fn-fs
significantly reduced the activity (P = 0.005). Since
we have shown that Fn is inactive [6], removal of
the Fn-fs was likely responsible for reduction in
cartilage damage activity.
The three Fn and Fn-f solutions derived after
recovering bound material from the affinity resins
were concentrated back to the original volumes of
the respective synovial fluids. Each solution was
then added to two DMEM/cartilage culture wells,
using the same volumes used in the synovial fluid
cultures. The eluted solutions caused an average
reduction in PG content to 23 ( 2 ) 2.3 (N = 6), a
value significantly different (P Q 0.0001) than that
for DMEM treatment alone, suggesting that the
enriched Fn and Fn-f mixture was active.
Zymography on gelatin acrylamide gels of these
eluted solutions did not show gelatinase bands
(data not shown), confirming that the affinity
isolation did not reduce activity of the synovial
fluid, by trapping proteinases onto the resin. As an
additional control, synovial fluid was passed over
a nonspecific goat antibody column and added to
cartilage cultures. The cartilage PG content after
5 days was 21.9 ( 2 ) 4.1 mg PG/mg cartilage, not
significantly different than that of the average of
the three untreated OA synovial fluids.
Fn-fs were generated by addition of IL-1a to
normal bovine articular cartilage in culture
We next investigated whether the Fn-fs could be
generated in cartilage damaged by a well-known
mediator of damage, IL-1a, which also induces
MMPs. Bovine articular cartilage was incubated
in serum-free DMEM with IL-1a. About 20% of the
total PG was released into the media by day 7, 42%
by day 14 and 65% by day 21. Serum-free conditions
were used to avoid contamination with serum
proteins, including native Fn. Concentrates of the
media and tissue extracts were subjected to
Western blotting with goat anti-sera to human Fn
in order to visualize generation of Fn-fs. The
application of the high concentrations of proteins,
such as PGs, in the concentrates sacrificed
resolution of the Fn-fs in the extracts and often led
to smearing. Nonetheless, qualitative effects of
IL-1a on levels of Fn-fs were observed. Fig. 3(a)
shows that by day 7 the control tissue had released
high levels of Fn into the serum-free DMEM media
(lane 1). The Fn is seen in the form of reduced
subunits above the 200-kDa position. The corre-
sponding tissue extract also shows the presence of
Fn subunits, with very low levels of a 120-kDa Fn-f.
Treatment of cartilage for 7 days with IL-1a caused
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Fig. 3. Western blot of media and tissue extracts from IL-1 treated cultured cartilage. Cartilage in serum-free DMEM
was adjusted to 50 U/ml IL-1a for days 0–21 and media were changed every 2 days. Conditioned media and tissue were
removed at (a) 7 days, (b) 14 days and (c) 21 days. Tissue was subjected to extraction and both media and tissue
concentrated · 10. The volumes of media and extracts from the same cartilage wells were identical, so that similar
volumes of media or extract concentrates correspond to the same mass of cartilage. Aliquots were first reduced and
then subjected to Western blotting on an 8% acrylamide SDS gel. The blots were then reacted with goat anti-sera to
human Fn to analyze for the presence of Fn-fs. Lanes 1 and 2 in each panel show control media and tissue extract,
respectively. Lanes 3 and 4 in each panel show IL-1a treated media and tissue extract, respectively.
conversion of much of the native Fn into a 120-kDa
Fn-f. By day 14 (Fig. 3(b)), the control tissue extract
also showed conversion of Fn into a 120-kDa Fn-f.
Since the gels and Western blots for all lanes were
performed simultaneously with the same reagents,
it would appear that more Fn was found in the
control tissue extract at day 14. Treatment with
IL-1a appeared to additionally enhance levels of
50-kDa and 30-kDa Fn-fs within the cartilage.
Further, as with the control tissue, the levels of
total Fn material appeared to increase. Fn-fs were
not found in the conditioned media as also
observed at day 7. By day 21 [Fig. 3(c)], the 50-kDa
and 30-kDa bands were detectable in control
cartilage extracts and the Fn material appeared to
increase as compared with day 14. Treatment with
IL-1a greatly enhanced levels of 120-kDa, 80-kDa,
68-kDa, 43-kDa and 30-kDa Fn-fs. Similar exper-
iments were performed six times with much higher
levels of Fn-fs consistently found in IL-1a treated
cartilage. The lack of detection of Fn-fs in
conditioned media suggests that the Fn-fs gener-
ated within the cartilage were partially retained
and did not effuse out of the cartilage during the
2 days between media changes.
In another experiment IL-1a was removed after
7 days from the serum-free DMEM cultures and
extracts analyzed at day 14. The fragmentation
decreased in IL-1a treated cartilage to undetect-
able levels, suggesting that the fragmentation
required the continual presence of IL-1a. In
another experiment, adjustment of serum-free
cartilage cultures to 1 mg/ml MMP-3 for 7 days also
led to generation of the 120-kDa Fn-f (data not
shown).
Fn-fs added to cartilage tissue dissociated
with a half-life of about 7 days
The above data had suggested that Fn-fs were
generated within the cartilage tissue but were
retained within the cartilage for at least 2 days. We
next attempted to determine whether Fn-fs would
eventually dissociate from cartilage tissue and
thus contribute to synovial fluid Fn-fs in vivo.
Radio-labeled 29-kDa Fn-f or bovine serum albu-
min was added to the culture media of cartilage
tissue in 10% serum/DMEM and after 7 days, the
media were analyzed at various times for the
presence of label. Although binding of the Fn-f was
maximal within 1 h, a 7-day exposure was used to
inflict damage so dissociation from severely
damaged, rather than normal cartilage, would be
measured. Fig. 4 shows the kinetics of release of
labeled Fn-f and bovine serum albumen. Specificity
of the binding of the Fn-f was suggested by the
observation that very little bovine serum albumen
bound at day 7. Further, when a 10-fold excess of
unlabeled Fn-f was added 4 h before addition of
labeled Fn-f, over 72% of the binding was blocked.
The Fn-f bound at day 7 to the level of 0.8 ng/mg
cartilage or about 2.4 · 10 - 14 mol/mg. The ratio of
bound:free at day 7 without correction for
nonspecific binding was 0.03 at a concentration of
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Fig. 4. Cartilage content of radio-labeled Fn-f as a
function of time. Cartilage was incubated with 100 nm
125I-labeled Fn-f (w) or 100 nm 125I-labeled bovine serum
albumen (q) in 10% serum/DMEM for days 0–7 only. At
various times, cultured cartilage was removed, washed
several times with 10% serum/DMEM and subjected to
gamma counting. Day 0 corresponds to the removal of
the labeled proteins from the media and the beginning
of the monitoring of the media.
label that was washed out represented 75% of that
found before washing. The label that could be
washed out in this way decreased by day 14 to
insignificant levels. Overall, the data showed that
the half-life for effusion of the Fn-f into the media
was about 7 days. Some of the media were placed
in 6–8 kDa cut off dialysis tubing and dialyzed
exhaustively against DMEM and the amount of
retained label measured. The amount of label
decreased by only 7%, suggesting that the Fn-f had
not been degraded to small peptides. This material
was then concentrated, subjected to electrophor-
esis on an SDS 10% acrylamide gel, the gel blotted
and the blot subjected to autoradiography with
goat anti-sera to human Fn. A single 29-kDa band
was detected (data not shown), suggesting that the
dissociated Fn-f had not been degraded into
discernable fragments.
added Fn-f surrounded cells and dissociated
from the tissue within days
We next investigated the site of interaction of
exogenous Fn-f and the length of time exogenous
Fn-fs were retained within the tissue. Fig. 5 shows
that when biotinylated Fn-f was incubated with
cartilage in 10% serum/DMEM for 7 days, the label
surrounded the cells. Fig. 6 shows that when the
100 nm Fn-f, which suggested very weak binding to
the tissue. At day 7, two 1 h washes of at least 3 ml
each of DMEM were required before the label in
the washes became insignificant. The amount of
Fig. 5. Visualization of cartilage bound biotinylated Fn-f. Cartilage was incubated in the (a) absence or (b) presence
of 100 nm biotinylated Fn-f in 10% serum/DMEM for days 0–7 as described in Methods. Tissue was removed, subjected
to cryosectioning and slices reacted with 0.2 mg/ml avidin–horseradish peroxidase and DAB. The slices were
photographed at · 100.
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Fig. 6. Visualization of cartilage bound biotinylated Fn-f as a function of time. Cartilage was incubated with 100 nm
biotinylated Fn-f for days 0–7 in 10% serum/DMEM as described in Methods. At days 3 and 5 in culture, fresh labeled
Fn-f and media were added. At 7 days, biotinylated Fn-f was removed from the media for the rest of the culture. Tissue
was removed at various periods, subjected to cryosectioning and slices reacted with 0.2 mg/ml avidin–horseradish
peroxidase and DAB. The slices were photographed at · 10. A, C, E and G, respectively, show control cartilage at days
7, 14, 21 and 28. B shows cartilage incubated with Fn-f for days 0–7. D, F and H show cartilage treated with Fn-f for
days 0–7, but analyzed at days 14, 21 and 28, respectively.
Fn-f was then removed from the cultures, the
bound Fn-f was detectable for up to day 21. The
control sections on the left were reacted only with
avidin–horseradish peroxidase and show very low
nonspecific binding. On the right are sections at
days 7, 14 and 21. These sections show the Fn-f
mostly surrounding the chondrocytes with some
Fn-f on the superficial surface. The intensity of the
label decreased by day 28 to control levels.
Addition of a 10-fold excess of unlabeled Fn-f 4 h
before addition of labeled Fn-f caused only
background binding (data not shown).
Fn-fs were generated by addition of mmp-3 to
normal bovine synovial fluid
Bovine synovial fluid was adjusted to 5 mg/ml
activated MMP-3 to determine if MMP-3 at this
level could generate Fn-f from the resident Fn in
synovial fluid. At various times, the synovial fluid
was subjected to Western blot analysis. In order
not to generate Fn-fs by contaminants in
hyaluronidase, the fluids were not treated, which
resulted in smearing of bands. Nonetheless,
MMP-3 generated Fn-fs from synovial fluid. Fig. 7
shows that the Fn in control synovial fluid was not
degraded over a 21-day period. However, by day 6
the MMP-3 generated Fn-fs of 30-kDa to nearly
100-kDa. By day 17, the Fn-fs remaining ranged
from 14 to 68-kDa. It was interesting that the
synovial fluid counterparts of the higher molecular
weight Fn-fs observed in cartilage extracts in
Fig. 2 apparently were degraded.
isolation of bovine plasma, synovial fluid and
cartilage Fn and generation of Fn-fs
In order to determine if Fn-fs derived from
synovial fluid or cartilage Fn forms might be
equally as active as bovine plasma Fn-fs, native
Fns were isolated and activated MMP-3 used to
make Fn-fs as described in Methods. Fig. 8(a)
shows a 5% SDS gel of the isolated bovine plasma,
bovine synovial fluid and bovine cartilage Fns.
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Fig. 7. Western blot of MMP-3 digests of bovine synovial fluid. Bovine synovial fluid was adjusted to 5 mg/ml MMP-3
and aliquots removed, reduced and subjected to electrophoresis on a 10% acrylamide SDS gel, followed by Western
blotting. Blots were reacted with goat anti-sera to human Fn. Lane 1 shows control synovial fluid at day 0. The next
lanes show control (C) and MMP-3 treated fluid ( + ) at days designated (days 2, 6, 10, 14 and 17).
Fig. 8. SDS gels of isolated bovine plasma, synovial fluid and cartilage Fn forms and of MMP-3 generated Fn-fs. (a)
Purified Fn from bovine plasma (P), bovine synovial fluid (S) and bovine articular cartilage (C) were subjected to
electrophoresis on 5% acrylamide SDS gels. Samples were reduced. (b) MMP-3 digests at day 3.
530
Days
m
g 
P
G
 in
 m
ed
ia
/m
g 
ca
rt
il
ag
e
20
10
1 2 3 4
Control
0
Fn
Fn-f
Osteoarthritis and Cartilage Vol. 6 No. 4 241
Fig. 8(b) shows a 10% SDS gel of the respective
digests after 3 days. The Fn-fs generated, below the
subunit molecular weight of 210 and 230-kDa, were
140, 120, 68, 50, 30 and 20-kDa. Some of these were
similar in size to those obtained upon addition of
MMP-3 to synovial fluid or of addition of IL-1a to
cartilage. By day 9, a resident 50-kDa Fn-f was
found in all three samples. Therefore, all three Fn
forms are digestible with MMP-3 to similar sized
Fn-fs. Control experiments in which proMMP-3,
that had not been activated with APMA, was
substituted for activated MMP-3, and added to
the Fn forms, showed no significant digestion of
the native forms, suggesting that activation of the
MMP was necessary for digestion.
mmp-3 generated plasma, synovial fluid and
cartilage Fn-fs were equally active
The activities of the MMP-3 digests, at day 3,
were then tested by measuring the kinetics of
release of PG into the media in serum-free cultures.
Serum was deleted from the media in order to
enable faster rates of hydrolysis under conditions
in which we have shown a clear dose-dependent
effect with Fn-f [6]. Fig. 9 shows that the native Fn
forms were inactive as also shown earlier for
native human plasma Fn [6]. However, all three
Fn-f mixtures were equally active in rates of
removal of PG from cartilage in serum-free
cultures. The rate of release of PG for the 1 mm Fn-f
digests was similar to that reported for 1 mm human
plasma 29-kDa Fn-fs [6]. Controls in which the Fn
forms were treated with proMMP-3, that had not
been activated with APMA, and then the resultant
solutions added to cultures, showed no significant
PG loss (data not shown). Also, activation of
pro-MMP-3 with APMA, followed by affinity
chromatography of the solution over Procion
Red–Sepharose and addition of this solution to
cartilage cultures, did not cause significant PG
depletion above controls with no Fn-f added,
suggesting that the PG depletion was due to acti-
vated MMP-3 and not a non-MMP-3 contaminant.
Discussion
Several aspects that related to the physiological
significance of Fn-fs were investigated. The highly
cartilage chondrolytic amino-terminal 29-kDa Fn-f
[6] and other larger amino-terminal Fn-fs were
detected in RA and OA cartilage, consistent with
our earlier report of Fn-fs in synovial fluids of
patients with OA [5]. There was very little 29-kDa
Fn-f or native Fn present in normal cartilage. The
RA and OA cartilages also showed high levels of
native Fn, consistent with observations of higher
levels of Fn in synovial fluids of patients with RA
and OA [1–5]. Thus, our continuing characteriz-
ation of the ability of the 29-kDa amino-terminal
Fn-f to regulate cartilage metabolism should have
relevance to pathologic processes involved in RA
and OA.
Removal of Fn and Fn-fs from the OA synovial
fluids significantly reduced the cartilage damaging
activity of the fluids. Since native Fn is inactive in
cartilage chondrolysis [6], these data suggest that
removal of Fn-fs has decreased the cartilage-
damaging activities of the OA synovial fluid. Thus,
the Fn-fs found in OA synovial fluid likely
contribute to the damage activity.
Fn-fs of 14-kDa up to 100-kDa were generated by
action of MMP-3 on synovial fluid. MMP-3 was
tested because IL-1 induces MMP-3, both synovial
tissue and cartilage express MMP-3, MMP-3 is
elevated in arthritis and MMP-3 has also been
shown to generate 40–200-kDa Fn-fs from purified
human plasma Fn [16, 17]. Our results were also
consistent with recent work that showed that not
only MMP-3, but also MMP-1 and MMP-2
(gelatinase A) released 22-kDa and 67-kDa N-
terminal Fn-fs, 21-kDa C-terminal Fn-f and 80-kDa
cell-binding Fn-fs from human plasma Fn [25].
Their work demonstrated that these respective
Fig. 9. Cartilage damage rates of Fn-fs in serum-free
culture. Bovine articular cartilage cultures were
adjusted to 1 mm in total Fn-fs in serum-free DMEM and
aliquots removed each day to assay PG using the DMB
assay. Each datum is the average and standard deviation
of three similar culture wells. The assays are shown for
a typical experiment from one bovine cartilage prep-
aration. Two other cartilage preparations, collected on
different days, showed similar results. Lower curves
correspond to control (q); bovine plasma Fn (w); bovine
synovial fluid Fn (r); bovine cartilage Fn (t). Higher
curves correspond to 1 mm human of human plasma Fn-fs
(q); bovine plasma Fn-fs (w); bovine synovial fluid Fn-fs
(r); and bovine cartilage Fn-fs (t).
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domains were inert in the intact Fn molecule, but
were activated by proteolytic treatment which
released the Fn-fs, a concept consistent with our
observations [6].
The observation that MMP-3 degraded Fn in
bovine synovial fluids was surprising because
the fluids likely contain not only alpha-2-
macroglobulin but also other inhibitors, such as
the well-characterized tissue inhibitors of MMPs,
namely TIMPs. Their presence in normal and OA
and RA synovial fluids has been well documented
[26, 27]. Nonetheless, these data suggest that
MMP-3 in synovial fluids is capable of generating
Fn-f which would damage cartilage.
Addition of IL-1a to cultured cartilage generated
Fn-fs similar in size to those generated upon
addition of MMP-3 to synovial fluid or to cartilage
Fns. Control cartilage not treated with IL-1a
gradually showed some fragmentation into the
same sized Fn-fs, but to a much smaller degree than
with IL-1a. The Fn-fs in control tissue likely arise
from normal rates of Fn turnover. However, since
these levels were significant and easily detected, it
may suggest that the effects of Fn-fs on MMP
induction and regulation of cartilage metabolism
as described by us [28] may be occurring to a small
extent in normal cartilage. We must assume that
the effects are limited since only higher levels of
Fn-fs cause very significant PG loss and MMP
induction [5, 10, 13, 28], events not observed in our
typical control cartilage.
When Fn-fs were generated within the tissue by
addition of IL-1a, they were not detectable within
the media for at least 2 days, consistent with the
7 day half-time for effusion of the labeled 29-kDa
Fn-f added to the cartilage. Although this suggests
a relative degree of retention of the Fn-fs, it also
suggests that eventually, cartilage generated Fn-fs
would enter the synovial fluid. This also suggests
that the Fn-fs might slowly accumulate in the
tissue and become more concentrated. Thus, over
time, conditions that would lead to only low levels
of Fn-fs may eventually cause damage to the extent
expected at high concentrations. This suggestion is
consistent with observations that as the concen-
tration of Fn-fs added to cultured cartilage is
lowered, longer lag periods occur before damage
begins, but the degree of damage eventually
becomes maximal [28].
The binding studies showed that when 100 nm
29-kDa Fn-f was incubated with cartilage, only
0.8 ng bound/mg cartilage or 5 · 1011 Fn-f
molecules/mg cartilage. Based on about 30 000
chondrocytes/mg cartilage, we can estimate that 16
million Fn-f molecules bound per chondrocyte,
consistent with earlier data [9]. These data suggest
that this particular Fn-f has a relatively high
number of binding sites within the tissue. This is
consistent with our earlier proposal that this Fn-f
may bind the very abundant matrix component,
PG, and this interaction may help increase the
intra-tissue concentration of the Fn-f and enhance
localization around the pericellular PG rich
matrix of the chondrocytes [9].
Our published studies have been of Fn-fs derived
from human plasma Fn and not of Fn-fs derived
from the most likely sources of Fn in the knee joint,
synovial fluid Fn and cartilage Fn. Fn-fs from these
different sources might have different activities
since they are known to occur in different isoforms
[29–35]. Therefore, MMP-3, because of its rele-
vancy to OA and RA, was used to generate
mixtures of Fn-fs from these sources. The mixtures
were as active as bovine or human plasma Fn-f
mixtures, derived by cathepsin D and thrombin
digestion [6]. We did not isolate specific Fn-fs and
test them because most of the Fn-fs spanning the
Fn subunit are active [6].
We have reported relatively high levels of Fn-fs
of up to 1 mm in OA synovial fluid [5]. At first
inspection, it might be assumed that any active
role for Fn-fs in OA would be performed by this
high concentration of Fn-fs in the synovial fluid. In
fact, a 2–5 ml volume of synovial fluid in the human
knee joint could contain at least 1 mg of Fn-fs.
However, cartilage exposed to proteinases might
generate enough Fn-fs to contribute to damage in
the absence of a contribution from synovial fluid
Fn-fs. For example, if a typical human knee joint
contains 20 g cartilage and each gram of cartilage
contains about 0.5 mg Fn, a steady state conver-
sion of 10% of the cartilage Fn into Fn-fs would
result in generation of about 1 mg Fn-fs, the
amount found in synovial fluid. Since the loss of
PG in OA or IL-1 treated cartilage can be up to
50%, as shown here, a 10% degree of fragmentation
is very likely. Further, if only 10% of the cartilage
Fn were degraded and the resultant Fn-fs
partitioned into the fluid volume of about
0.75 ml/mg cartilage, the resultant intra-tissue Fn-f
concentration would be up to 100 nm for any Fn-f.
This concentration added to cartilage cultures
results in very severe PG depletion and damage
[13, 15]. If the Fn-fs are partially retained within
the tissue as shown here, the tissue Fn-f levels may
be much higher. Thus, Fn-f levels found in
damaged or OA cartilage may be similar to those
found in OA synovial fluids and may be sufficient
for amplifying cartilage damage without the
involvement of synovial fluid Fn-fs.
These data support the notion that elevated
proteinases in synovial fluids can generate Fn-fs
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from synovial fluid Fn and these Fn-fs can
penetrate cartilage and cause damage. This would
also lead to generation of cartilage Fn-fs, since
Fn-fs can enhance proteinases that, in turn,
generate more Fn-fs as shown here. However, the
data also support the possibility that elevated
proteinases within the cartilage tissue can gener-
ate sufficient Fn-fs to amplify Fn-f driven cartilage
damage, without the involvement of synovial fluid
Fn-fs. Either or both processes may occur in vivo
and both illustrate that Fn-fs should be considered
potential autocrine and paracrine regulators of
cartilage metabolism.
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